Guy's and St Thomas' NHS Foundation Trust

Specialist MDT: Guy's and St Thomas' NHS Foundation Trust

View Provider Services

Men diagnosed at this hospital trust can access the following services:

  • Diagnostic Facilities:
    • Multiparametric MRI
    • Transperineal biopsy under local anaesthetic
    • Transperineal biopsy under general anaesthetic
    • Choline PET
    • PSMA (prostate-specific membrane antigen) PET scan
    • Whole body MRI
    • Isotope bone scan
  • Treatment Facilities:
    • Robot assisted laparoscopic prostatectomy
    • External beam radiotherapy
    • Intensity-modulated radiotherapy
    • Low-dose rate brachytherapy
    • Stereotactic body radiation therapy (SBRT)
    • Chemotherapy
    • Joint specialist MDT clinic
  • Support Service Facilities:
    • Prostate cancer clinical nurse specialist (PCa CNS)
    • Advanced PCa CNS
    • Urology CNS
    • Oncology CNS
    • Sexual function services
    • Specialist continence services
    • Psychological counselling

Data Quality

Diagnosing Trust Specialist MDT
No. of Cancer Registry records 487 1113
Performance Status recorded 22% 40%
PSA completed 40% 65%
Gleason Score completed 80% 84%
TNM completed 83% 76%
Multiparametric MRI performed 38% 34%
At least 1 treatment modality recorded 7% 14%

Disease Presentation

Specialist MDT National
No. of men with disease status determined 978 39295
Percentage of men diagnosed with metastatic disease 11% 16%

Management

Specialist MDT National
No. of men diagnosed with low-risk localised disease 64 2581
Percentage of men with low-risk localised disease receiving radical treatment 4% 4%
No. of men diagnosed with locally advanced disease 347 15573
Percentage of men diagnosed with locally advanced disease receiving radical treatment 63% 68%
No. of men with high risk/locally advanced prostate cancer who received radiotherapy 163 6974
Percentage of men having radical radiotherapy for high-risk/locally advanced disease receiving a brachytherapy boost 0% 5%
No. of men diagnosed with N+ M0 (node positive, no metastases) 49 1821
Percentage of men diagnosed with N+ M0 (node positive, no metastases) receiving docetaxel 17% 14%
No of men diagnosed with M1 (metastases) 104 6085
Percentage of men diagnosed with M1 (metastases) receiving docetaxel 26% 27%
Diagnosing Trust National
No. of men diagnosed with intermediate-risk disease 99 3457
Percentage of men diagnosed with intermediate-risk disease receiving a hypofractionated regimen 86% 91%
No. of men of men diagnosed with high-risk disease 167 6966
Percentage of men diagnosed with high-risk disease receiving a hypofractionated regimen 45% 59%

Outcome

Treatment Centre
No. of men who received radical prostatectomy (2017-2018) 277
Adjusted percentage of men who had an emergency readmission within 90 days of radical prostatectomy (%) 7%
No. of men who received radical prostatectomy (2016) 189
Adjusted percentage of men experiencing at least one GU complication (%) 2%
No. of men who received radical radiotherapy (2016) 211
Adjusted percentage of men experiencing at least one GI complication (%) 16%

Compare provider outcomes